Recruiting

Observational Study

Sponsor:

Rocket Pharmaceuticals Inc.

Code:

NCT06644742

Conditions

Cardiomyopathies

Heart Diseases

Cardiovascular Diseases

Genetic Diseases

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.

Conditions

Cardiomyopathies

Heart Diseases

Cardiovascular Diseases

Genetic Diseases

Study ID

NCT06644742

Start date

Mar, 2026

Status verified date

Feb, 2026

Completion date

Apr, 2031

Anticipated

Primary completion date

Dec, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Inclusion Criteria

Patients must meet all the following criteria (and none of the exclusion criteria) to be eligible for study participation:

1. Male or female age 12 years or older at the time of providing informed consent (i.e., ICF provision).
2. Capable and willing to provide signed informed consent and/or assent, which includes compliance with the requirements and restrictions listed in the ICF and protocol.
3. Clinical diagnosis of arrhythmogenic cardio myopathy (ACM)
4. Documentation of a pathogenic or likely pathogenic variant in PKP2 by a CLIA-certified genetic testing laboratory
5. History of ICD implantation ≥6 months prior to ICF provision
6. Left ventricular ejection fraction by echocardiogram or cardiac magnetic resonance (CMR) ≥50% at ≤12 months prior to ICF provision

Exclusion Criteria

Patients meeting any of the following criteria are excluded from study participation:

1. Gene testing indicates that the subject's arrhythmia or cardiomyopathy may be related to a genetic etiology other than PKP2 truncating variant.
2. Concurrent participation in any other clinical investigation involving use of an investigational agent that could confound results of this study.
3. Previous participation in a study of gene transfer or gene editing.
4. NYHA Class IV heart failure.
5. Presence or requirement for mechanical circulatory support (MCS) or predicted need for MCS or heart transplantation within 6 months of enrollment.
6. Prior cardiac or other organ (lung, liver, other) transplantation.
7. Pacemaker dependent rhythm documented, as assessed by the principal investigator ≤12 months prior to enrollment.
8. Positive human immunodeficiency virus (HIV) antibody test.
9. Unwillingness to comply with study procedures, including follow-up as specified by this protocol, or unwillingness to fully cooperate with the investigator.

Study Design

Enrollment

36 participants

Anticipated

Interventions and Outcome Measures

Arms

Prospective and Retrospective Cohort (No Intervention)

Primary outcome measure

  • Heart rhythm and rate monitoring measures [ Time Frame: 36 months ]
  • Cardiac biomarkers [ Time Frame: 36 months ]

Central Contacts and Locations

Central contacts

Locations

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02116

Contacts

Principal Investigator:

Dominic Abrams, MD

Duke University

Recruiting

Durham, North Carolina, United States, 27710

Contacts

Principal Investigator:

James Daubert, MD

More Information

Sponsor

Rocket Pharmaceuticals Inc.

Last update posted

Feb 27, 2026

Last verified

Feb, 2026

Keywords

  • Arrhythmogenic Cardiomyopathy
  • Plakophilin-2
  • Arrhythmogenic Cardiomyopathy (AC, ARVD/C)
  • PKP2

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Rocket Pharmaceuticals Inc. on 2026-02-27.